GlassScriptPhysician profile
Amee Mehta
NPI 1760627814
$551.35
in general payments reported to CMS, 2019-2025
11 companies · $33.89 in 2025
The $33.89 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $16.24 · 2021: $101 · 2022: $174 · 2023: $47.56 · 2025: $33.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.95 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $113.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.40 | 2021-2022 | |
| Novo Nordisk INC | $72.42 | 2021-2025 | Wegovy |
| Csl Behring | $37.53 | 2019 | |
| Boston Scientific Corporation | $29.49 | 2023 | Watchman Access System |
| Abbvie INC. | $23.77 | 2022 | |
| Merck Sharp & Dohme LLC | $18.07 | 2023 | Verquvo, Bridion |
| Allergan, INC. | $16.24 | 2020 | |
| Neurocrine Biosciences, INC. | $14.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amee Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.